Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
- Bottle Label 100 mg - 71610 0465 30
- Aphena Pharma Solutions - TN - Aphena
- Figure-1 - Losartan Fig1
- Figure-2 - Losartan Fig2
- Figure-3 - Losartan Fig3
- Figure-4 - Losartan Fig4
- Structure - Losartan Struct
- Table-2 - Losartan Table2
- Table-3 - Losartan Table3
- Table-4 - Losartan Table4
- Table-5 - Losartan Table5
Product Label Images
The following 11 images provide visual information about the product associated with Losartan Potassium NDC 71610-465 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Bottle Label 100 mg - 71610 0465 30
Aphena Pharma Solutions - TN - Aphena
Figure-1 - Losartan Fig1
This appears to be a chart or table showing the results of a study on patients with primary endpoints who were treated with either Atenolol or Losartan Potassium. The chart shows an adjusted risk reduction of 13% for the latter drug, with a p-value of 0.021. The x-axis appears to show the timeline of the study in months.*
Figure-2 - Losartan Fig2
This text shows the percentage of patients who had a fatal/non-fatal stroke while taking Atenolol or Losartan Potassium. The adjusted risk reduction for Losartan Potassium was 25%, with a p-value of 0.001. The chart also displays the study month timeline for up to 66 months.*
Figure-3 - Losartan Fig3
Figure-4 - Losartan Fig4
Structure - Losartan Struct
Table-2 - Losartan Table2
This is a table showing pharmacokinetic parameters in hypertensive adults and children between the ages of 6 and 16, following multiple dosing of 50 mg once daily for adults and 0.7 mg/kg once daily for children. The table displays the number of participants in each group, as well as various pharmacokinetic parameters such as the parent active metabolite and AUC (area under the curve). Additionally, mean, harmonic mean, and median values are provided for certain parameters.*
Table-3 - Losartan Table3
This is a tabular data showing the incidence of primary endpoint events with Losartan and Potassium Atenolol. The primary composite endpoint, components of the primary composite endpoint, and the rate per 1000 patient-years of follow-up are listed. The text seems to be a result of a clinical trial.*
Table-4 - Losartan Table4
Table-5 - Losartan Table5
Table 5 shows the efficacy results for different demographic subgroups based on a study comparing the use of Rosils, Losartan, and placebo. The primary endpoint, event rate, hazard ratio, and confidence interval are reported for each subgroup. The subgroups analyzed include age, race, and ethnicity. The study found significant differences in outcomes between some subgroups, with Rosils and Losartan showing improved efficacy compared to placebo.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
